Table 5.
HER2 | ER | HbT | %US_EOC1 | %HbT_EOC1 | %HbT_EOC3 | |
---|---|---|---|---|---|---|
| ||||||
HER2, ER | 2.561 | 2.026 | ||||
HER2, ER, HbT | 2.342 | 1.866 | 0.027 | |||
HER2, ER, %US-EOC1 | 2.442 | 2.102 | − 0.056 | |||
HER2, ER, %US_EOC1, %HbT_EOC1 | 2.010 | 2.179 | − 0.0711 | − 0.075 | ||
HER2, ER, %US_EOC1, %HbT_EOC3 | − 0.121 | 3.079 | − 0.098 | − 0.196 | ||
HbT | 0.038 | |||||
%US_EOC1 | − 0.078 | |||||
%US_EOC1, %HbT_EOC1 | − 0.093 | − 0.077 | ||||
%US_EOC1, %HbT_EOC3 | − 0.078 | − 0.134 |
Data were from this study of total 38 patients